Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, and Hematological disorders and diagnostics.
Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells
A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia
Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes
Altered Structure and Function of Mesenchymal Stromal Cell-Derived Extracellular Matrix in MDS Can be Restored By Luspatercept
Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network
Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial
Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data
Activin Receptor Modulation
Myelodysplastic syndromes and bone loss in mice and men
Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors
Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts
Epigenetic Biomarkers Are Applicable for Risk Stratification in Myelodysplastic Syndromes
Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience